

# Consolidated Statement of Income

Mitsubishi Tanabe Pharma Corporation and Consolidated Subsidiaries

(Millions of yen)

|  | FY 2017 | FY 2018        |
|--|---------|----------------|
| <b>Revenue</b>   | 433,855 | <b>424,767</b> |
| <b>Cost of sales</b>   | 169,750 | <b>180,646</b> |
| <b>Gross profit</b>  | 264,105 | <b>244,121</b> |
| Selling, general and administrative expenses                                       | 104,055 | <b>98,725</b>  |
| Research and development expenses  | 79,083  | <b>86,533</b>  |
| Amortization of intangible assets associated with products                         | 2,451   | <b>2,934</b>   |
| Other income   | 6,661   | <b>1,481</b>   |
| Other expenses   | 7,915   | <b>7,027</b>   |
| Share of profit of associates and joint ventures accounted for using equity method | 23      | –              |
| Share of loss of associates and joint ventures accounted for using equity method   | –       | <b>80</b>      |
| <b>Operating profit</b>  | 77,285  | <b>50,303</b>  |
| Financial income   | 1,881   | <b>1,253</b>   |
| Financial expenses   | 402     | <b>1,117</b>   |
| Profit before income tax   | 78,764  | <b>50,439</b>  |
| Income tax expenses  | 24,772  | <b>18,223</b>  |
| <b>Profit for the year</b>   | 53,992  | <b>32,216</b>  |
| <b>Profit attributable to:</b>   |         |                |
| Owners of the Company  | 57,963  | <b>37,372</b>  |
| Non-controlling interests  | (3,971) | <b>(5,156)</b> |
| Profit for the year  | 53,992  | <b>32,216</b>  |
| <b>Earnings per share</b>  |         |                |
| Basic earnings per share   | 103.35  | <b>66.64</b>   |
| Diluted earnings per share   | 103.35  | <b>66.64</b>   |